Skip to main content
Premium Trial:

Request an Annual Quote

SomaLogic to Receive Up to $60.5M in Funds From Visium

NEW YORK (GenomeWeb) – SomaLogic said today that it will receive up to $60.5 million in debt and equity financing from Visium Healthcare Partners.

The company said it plans to use the funds to support the development of new life science tools and clinical diagnostics based on its Somamer affinity agent technology.

"SomaLogic's proprietary Somamer and Somascan technologies provide researchers and clinicians with a level of proteomic information that promises to revolutionize how diseases are diagnosed and treated," Visium Partner Avi Amin said in a statement. "We believe that SomaLogic is an incredibly compelling emerging healthcare company and expect that this investment will help accelerate the realization of their ambitious vision and vast potential."

Somalogic's Somamers are essentially short strands of DNA that bind to protein targets in samples of interest. They can then be quantified via microarrays, with the quantity of a given Somamer corresponding to the quantity of its target protein. The company's Somascan product consists of an array of Somamers to 1,310 different protein targets.

To date, the bulk of Somalogic's revenues have come from sales of Somascan services and platforms, but in a statement announcing the Visium deal, Founder and Chairman Larry Gold highlighted the company's diagnostic development ambitions, noting that the new capital would provide it "the opportunity to even more quickly realize our ultimate goal of delivering much-needed new diagnostics tests to the clinic."

Terms of the agreement were not disclosed.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.